“We don't have time for July....” False. CY
Post# of 148190
(Total Views: 669)
Posted On: 05/31/2020 1:26:09 PM
Re: Rubraquercus #36038
“We don't have time for July....”
False. CYDY has between now and about September, or the beginning of fall, to release promising results. Right now everyone’s concern is a a second wave starting in the fall and going through winter. I’m confident data from both the mild/moderate and severe trial will be released by then. The question is what will the FDA do with it?
“Russian Health Ministry Approves Anti-Coronavirus Drug Avifavir.”
We already know that antivirals aren’t the answer. If anti-vitals aren’t given early, they don’t reduce hospitalizations or deaths. In the case of Tamiflu, used for the treatment of influenza, it’s recommended for the majority of patients that the drug be started within 48 hours of onset of symptom. This is difficult as not everyone’s symptoms are severe in the first 48 hours and may be considered as cold symptoms (which Tamiflu is not used for).
I’d also like to point out some red flags related to Avifavir. First, the drug was developed by, “ a joint venture of the Russian Direct Investment Fund and ChemRar Group“. Usually drugs are developed by partnerships between BPs and/or national health institutes, not by a Russian investment fund. Usually a doctor is quoted in press releases regarding clinics drugs, but in this case, it was the CEO of the investment fund. That’s concerning. That’s like the leader of a hedge fund, who invested in a biotech to make profit, commenting on the drugs success in a medical publication.
“Avifavir is not only the first antiviral drug registered against coronavirus in Russia, but it is also perhaps the most promising antiCovid-19 drug in the world,” Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said in the statement late Saturday.“
This is about Russia making money. Additionally, there is no statistically significant data from a controlled, double-blinded clinical trial showing Avifavir is actually effective in fighting COVID19. Trials are ongoing in India at the moment. At least Remdesevir showed some benefit in a legit clinical trial, although it also didn’t reduce hospitalizations or deaths.
False. CYDY has between now and about September, or the beginning of fall, to release promising results. Right now everyone’s concern is a a second wave starting in the fall and going through winter. I’m confident data from both the mild/moderate and severe trial will be released by then. The question is what will the FDA do with it?
“Russian Health Ministry Approves Anti-Coronavirus Drug Avifavir.”
We already know that antivirals aren’t the answer. If anti-vitals aren’t given early, they don’t reduce hospitalizations or deaths. In the case of Tamiflu, used for the treatment of influenza, it’s recommended for the majority of patients that the drug be started within 48 hours of onset of symptom. This is difficult as not everyone’s symptoms are severe in the first 48 hours and may be considered as cold symptoms (which Tamiflu is not used for).
I’d also like to point out some red flags related to Avifavir. First, the drug was developed by, “ a joint venture of the Russian Direct Investment Fund and ChemRar Group“. Usually drugs are developed by partnerships between BPs and/or national health institutes, not by a Russian investment fund. Usually a doctor is quoted in press releases regarding clinics drugs, but in this case, it was the CEO of the investment fund. That’s concerning. That’s like the leader of a hedge fund, who invested in a biotech to make profit, commenting on the drugs success in a medical publication.
“Avifavir is not only the first antiviral drug registered against coronavirus in Russia, but it is also perhaps the most promising antiCovid-19 drug in the world,” Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said in the statement late Saturday.“
This is about Russia making money. Additionally, there is no statistically significant data from a controlled, double-blinded clinical trial showing Avifavir is actually effective in fighting COVID19. Trials are ongoing in India at the moment. At least Remdesevir showed some benefit in a legit clinical trial, although it also didn’t reduce hospitalizations or deaths.
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼